Trial reportObesity surgery2025
Eleven-Year Outcomes of a Randomized Controlled Trial Comparing Standard and Distal Roux-en-Y Gastric Bypass in Patients with BMI Above 50 kg/m².
Trial report in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term outcomes of standard Roux-en-Y gastric bypass (RYGB) compared with distal Roux-en-Y gastric bypass (DRYGB) in patients with BMI > 50 kg/m² remain inadequately defined. This study presents 11-year follow-up results from a previously published randomized controlled trial comparing standard RYGB with DRYGB configured with a 200 cm biliopancreatic limb and 150 cm common channel.
methodsOne hundred and forty patients with BMI > 50 kg/m² were randomized to standard RYGB (n = 76) or DRYGB (n = 64). Primary outcomes were long-term weight loss and resolution of associated medical problems. Secondary outcomes included surgical complications, nutritional deficiencies, and gastrointestinal symptoms. Follow-up involved individual interview and laboratory analyses.
resultsAfter 11.1 (± 1.4) years, DRYGB yielded a greater reduction in BMI units (20.7 vs. 15.5) and higher total weight loss (37.1% vs. 29.4%) than standard RYGB, with fewer cases of suboptimal weight loss (15% vs. 35%) and a higher proportion achieving BMI < 40 kg/m² (78.8% vs. 54.4%). Diabetes remission was achieved in 91.7% of DRYGB patients compared with 78.6% following standard RYGB. Nutritional deficiencies (albumin, ferritin, vitamin E, zinc and parathyroid hormone) were more common after DRYGB. Greater severity of dumping and increased stool frequency were observed after DRYGB, whereas diarrhea rates were comparable between groups.
conclusionDRYGB resulted in superior weight loss and metabolic outcomes compared to standard RYGB, while maintaining a manageable profile of nutritional deficiencies. These findings endorse DRYGB as a durable surgical option in patients with BMI > 50 kg/m², contingent upon structured lifelong follow-up.
Indexed as
Identifiers
41201756What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.